MarketPulse

GLP-1 receptor agonist

7 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Novo Nordisk Showcases Obesity Portfolio at European Congress With Wegovy Data, CagriSema Focus

Novo Nordisk will present 52 abstracts on Wegovy and experimental CagriSema at European obesity congress, highlighting cardiovascular benefits and women's health data.
NVOclinical dataweight loss
BenzingaBenzinga··Vandana Singh

Novo Nordisk Advances Oral GLP-1 Therapy for Young Diabetics

Novo Nordisk reports positive phase 3a trial results for oral semaglutide in children with type 2 diabetes, planning 2026 regulatory filings for potential first pediatric GLP-1 approval.
NVOregulatory approvalOzempic
The Motley FoolThe Motley Fool··Adria Cimino

Lilly's Retatrutide Could Cement Dominance in Surging Weight Loss Drug Market

Eli Lilly controls 60% of U.S. weight loss market with $11B+ quarterly revenue. Pipeline drug retatrutide showing 28% weight reduction could extend lead over Novo Nordisk.
LLYNVOclinical trialsweight loss drugs
GlobeNewswire Inc.GlobeNewswire Inc.··Structure Therapeutics Inc.

Structure Therapeutics' Aleniglipron Posts Blockbuster Phase 2 Data, Rivaling Injectable GLP-1s

Structure Therapeutics reports Phase 2 data for oral GLP-1 agonist aleniglipron showing 16.3% weight loss, matching injectable competitors with better tolerability.
GPCRPhase 2 clinical trialFDA approval
BenzingaBenzinga··Vandana Singh

Pfizer's Weight-Loss Drug Wins China Approval, Intensifying GLP-1 Competition

Pfizer wins NMPA approval for weight-loss drug ecnoglutide in China, achieving 15.4% average weight loss in trials, intensifying competition as Novo Nordisk's Wegovy faces patent expiry.
PFELLYNVOclinical trialweight-loss drug
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

GLP-1 Drug Market Poised to Triple to $202B by 2033 Amid Obesity Surge

Global GLP-1 receptor agonist market projected to grow from $70B in 2025 to $202B by 2033 at 12.78% annual rate, driven by obesity and diabetes prevalence.
LLYSNYNVOAZNIVBIYclinical trialsmarket growth
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Advances Obesity Treatment Pipeline Ahead of 2026 Trial Milestones

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.
LLYNVOVKTXbiotechclinical trials